BG
CYTO

Bellevue Group’s Altamira Therapeutics Ltd CYTO Stock Holding History

Bellevue Group’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-24
Closed -$151K – 143
2018
Q2 		$151K Sell
24
-3
-11% -$31.7K 0.01% 138
2018
Q1 		$347K Hold
27
– – 0.03% 124
2017
Q4 		$1.28M Hold
27
– – 0.13% 99
2017
Q3 		$1.78M Hold
27
– – 0.19% 83
2017
Q2 		$1.55M Hold
27
– – 0.18% 91
2017
Q1 		$2M Hold
27
– – 0.27% 79
2016
Q4 		$2.32M Hold
27
– – 0.48% 56
2016
Q3 		$3.75M Hold
27
– – 0.68% 49
2016
Q2 		$9.09M Hold
27
– – 1.71% 17
2016
Q1 		$7.9M Buy
+27
New +$9.61M 1.43% 20

Other funds holding CYTO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Group's CYTO Position: Q3 2018 in Review

Bellevue Group sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2018, closing a stake of 24 shares — an estimated $151K sold.

Bellevue Group first reported a position in CYTO in Q1 2016 and held it in 10 quarters. The position peaked at $9.09M in Q2 2016. 7 funds tracked by Wall St. Rank hold CYTO as of Q3 2018.

  • Bellevue Group reported no remaining Altamira Therapeutics Ltd position as of Q3 2018 after selling out during the quarter.
  • Bellevue Group sold 24 Altamira Therapeutics Ltd shares in Q3 2018, an estimated $151K.
  • Bellevue Group first reported a position in Altamira Therapeutics Ltd in Q1 2016 and held it in 10 quarters.
  • Bellevue Group's Altamira Therapeutics Ltd position peaked at $9.09M in Q2 2016.
  • 7 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2018.

Based on Bellevue Group's 13F filing for Q3 2018, filed 13 Nov 2018.